{
 "PrintNo":"A7928","Session":2021,"Chamber":"ASSEMBLY","BillType":"Assembly","Published":"2021-06-01T11:07:10.627015Z",
 "Status":"IN_ASSEMBLY_COMM","Committee":"Health",
 "Milestones":[{"Type":"IN_ASSEMBLY_COMM","Date":"2022-01-05","Committee":"Health"}],
 "Actions":[
  {"Text":"REFERRED TO HEALTH","Date":"2021-06-01","Chamber":"ASSEMBLY"},
  {"Text":"REFERRED TO HEALTH","Date":"2022-01-05","Chamber":"ASSEMBLY"}
 ],
 "Sponsors":[{"ID":520,"Name":"Linda Rosenthal","Short":"ROSENTHAL L"}],
 "Title":"Establishes the psychedelic research institute and the psychedelic substances therapeutic research program",
 "Summary":"Establishes the psychedelic research institute and the psychedelic substances therapeutic research program which shall study and provide recommendations regarding the use of psychedelic substances in the treatment of addictive disorders, depression, post-traumatic stress disorder, end-of-life anxiety and other pertinent outcomes.",
 "LawSection":"Public Health Law",
 "LawCode":"Add Art 27-G §§2788 - 2794, Art 33-AA §§3397-j - 3397-l, amd §3350, Pub Health L",
 "ActClause":"AN ACT to amend the public health law, in relation to establishing the psychedelic research institute and the psychedelic substances therapeutic research program"
}